For ChLIA PRISM and CIA VITROS the sensitivity was 98.2% (95% CI 95.8-99.2) and 96.3% (95% CI 93.9-97.8), specificity was 95.0% (95% CI 93.0-96.5) and 96.0% (95% CI 94.2-97.2), and the area under the curve was 0.987 (95% CI 0.981-0.994) and 0.978 (95% CI 0.969-0.987), respectively. CONCLUSION: Different signal to cutoff ratios with a high antibody level by PRISM and VITROS assays predict viremia
in people with hepatitis C and function as an accurate serologic marker to guide the use of routine HCV RNA testing to confirm hepatitis C infection. Table: Viremic status according to the anti-HCV level Viremic subjects are defined as positive HCV RNA No viremic subjects are defined as negative HCV RNA pp<0.001 Disclosures: The following people have nothing to disclose: Ana M. Contreras Background: In Switzerland approximately 30% of hepatitis C virus (HCV) infected individuals have been diagnosed. To enhance this rate, Ixazomib clinical trial new detection strategies are needed. The aim of this project was to analyze the distribution of HCV cases in Switzerland to develop better detection strategies. Methods: A previously described HCV disease burden model was populated with Swiss assumptions regarding HCV prevalence, viremic rate Roscovitine price and age distribution. The
viremic population was aged from 1998 to 2013 accounting for mortality and cure rates, and was stratified according to birth cohort. The number of screenings required to identify one viremic case was calculated as 1/(viremic HCV prevalence). Costs
in Swiss Francs (CHF) associated with diagnosing and genotyping one viremic case were estimated as follows – [CHF 25*(# anti-HCV tests administered)] + [CHF 180*(# HCV-RNA tests administered for anti-HCV positive cases)] + [CHF 180*(# genotype Thymidine kinase tests administered for HCV-RNA positive cases)]. Results: More than 50% of the viremic HCV infected population was born during 1954-1973, with 73% born during 1949-1978. Random screening would require >100 anti-HCV tests (in addition to further confirmatory tests) to find one current HCV case, while screening in the 1949-1978 cohort (36-65 years of age) could find one case per 59 persons screened. Screening in the 1949-1978 cohort would cost CHF 1,890 (USD $2,110) per positive diagnosis, as compared with a CHF 2,790 ($3,115) cost for random screening. Screening by 5-year cohort could find anywhere from one case per 56 screened (1974-1978 cohort, 12% of the viremic population) to one case per 5,855 screened (2009-2013 cohort, <1% of the viremic population) Conclusion: The most efficient birth-year screening strategy would target persons born between 1949 and 1978 (35 – 64 years of age), as this cohort accounts for over 70% of viremic cases and requires screening of only 59 individuals to identify one viremic HCV infected case.